- 著者
- 平野 貴大 Takahiro Hirano
- 出版者
- 同志社大学一神教学際研究センター(CISMOR)
- 雑誌
- 一神教世界 = The world of monotheistic religions (ISSN:21850380)
- 巻号頁・発行日
- vol.10, pp.99-119, 2019-03-31
本稿の目的は、現在のイランの最高指導者であるハーメネイーのシャイフ・ムフィード観を分析することで、現代のシーア派学者が同派とムウタズィラ派との教義上の類似性をどのように説明するのかを解明することである。その分析を通じて、ハーメネイーをムフィードの学統に繋がる中道的な法学者・神学者として位置づけることも目指す。欧米研究者の通説によれば、ムフィードはムウタズィラ派をイマーム派に導入した、もしくはムウタズィラ派に強く影響を受けた合理主義者であるとされる。ハーメネイーは欧米研究者のムフィード観を批判し、ムフィードは法学と神学における伝承主義と合理主義の中道的な学統の創始者であると主張した。シーア派がムウタズィラ派を導入したという主張を否定することは、ハーメネイー独自の学説ではなく、シーア派学者の間の定説となっていた。以上より、保守派/原理主義者とみなされる傾向にあったハーメネイーはムフィードの学統に繋がる中道的な法学者・神学者として再評価されるべきであるといえる。
- 著者
- Keiji Matsuoka Takahiro Hirano
- 出版者
- The Plankton Society of Japan, The Japanese Association of Benthology
- 雑誌
- Plankton and Benthos Research (ISSN:18808247)
- 巻号頁・発行日
- vol.15, no.3, pp.232-237, 2020-08-14 (Released:2020-08-04)
- 参考文献数
- 25
- 被引用文献数
- 1
A new species of viviparid gastropod belonging to the genus Heterogen Annandale, 1921, is described from the Pleistocene Katata Formation of the Kobiwako Group in the southern part of Lake Biwa, central Japan. This new species is continuously recorded from the Nijigaoka Clays (1.2 Ma) to the Hiraen Clays (0.8 Ma) of the Katata Formation. This new species, Heterogen praelongispira sp. nov. is similar to the extant H. longispira in Lake Biwa, but the details of shell morphology are different from those of H. longispira, including fine-to-deep suture, flattened whorl side, and oval shape of embryonic shell.
- 著者
- Koichiro Kinugawa Eisuke Nakata Takahiro Hirano Seongryul Kim
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-21-0926, (Released:2022-03-10)
- 参考文献数
- 22
- 被引用文献数
- 5
Background:OPC-61815, a prodrug of tolvaptan, is an injectable aquaretic drug. This study evaluated the tolerability of OPC-61815 in patients with congestive heart failure (CHF) who had difficulty with, or were incapable of, oral intake in a multicenter, uncontrolled, open-label Phase III study.Methods and Results:Forty-five patients were enrolled at 30 Japanese sites. OPC-61815 infusion was administered once daily; the 8 mg initial dose could be increased to 16 mg if the dose escalation criteria were met. Patients were treated for up to 5 days. Thirty-eight patients maintained the 8-mg dose and 7 had a dose increase to 16 mg; 41 completed the trial (34 completed early). One patient had mild hypernatremia. No significant safety concerns were observed with OPC-61815 administration at a starting dose of 8 mg and with dose escalation in accordance with the protocol-specified criteria. Treatment resulted in weight decrease (−3.01 kg); improvement or disappearance rates for other CHF symptoms (including edema, dyspnea, orthopnea, pulmonary congestion, and rales) indicated that treatment was effective. Urine excretion was increased 0–1 h after OPC-61815 administration and reached a maximum level at 1–2 h.Conclusions:The tolerability of once daily (up to 5 days) intravenous OPC-61815 (8 mg or 16 mg) was confirmed in patients with CHF who had difficulty with, or were incapable of, oral intake.